Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in San Francisco that focuses on developing therapies for women's cancers, specifically estrogen receptor-positive breast cancer. The company's lead candidate, palazestrant, is an estrogen receptor antagonist and selective ER degrader currently in Phase 3 clinical trials. Palazestrant is being evaluated both as a monotherapy in the OPERA-01 trial for second and third-line metastatic breast cancer and in combination with established cancer drugs including CDK4/6 inhibitors, PI3K alpha inhibitors, and mTOR inhibitors.

The company is also advancing OP-3136, a selective KAT6 inhibitor in early-stage development for estrogen receptor-positive metastatic breast cancer and other cancer types. Olema operates as a pre-revenue clinical-stage company with development activities centered on oncology indications where hormonal resistance represents a significant clinical challenge.

The company maintains a lean operational footprint with 122 full-time employees supporting its clinical development and corporate functions from its San Francisco headquarters. Olema was originally incorporated in 2006 and rebranded from CombiThera, Inc. in 2009. The company is listed on the Nasdaq and incorporated in Delaware.